SATURDAY, SEPTEMBER 5, 2026|No. 13909
Health · Nigeria · Pakistan

Nigeria Issues Warning Over Four Medicines Recalled in Pakistan Due to Quality Concerns

Nigeria's drug regulatory agency, NAFDAC, has alerted the public and healthcare professionals about four specific medicines recalled in Pakistan due to quality issues, urging caution and vigilance.

A Nigerian health official speaking at a press conference.
A Nigerian health official speaking at a press conference.
2 sources
Pipeline ingest
3 reads
Positive / Neutral / Negative
2 countries
Related coverage

Nigeria warns about four medicines recalled in Pakistan

Lev Shevtsov 04 September 2026 22:40

Nigeria warns about four medicines recalled in Pakistan

Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC) has warned healthcare workers, importers, distributors, sellers and the public about four medicines recalled by the Pakistani regulator due to quality issues.

As Premium Times Nigeria reports, Pakistan’s Drug Regulatory Authority (DRAP) recalled specific batches of Nitras and Kadin 2 tablets, Acefyl cough syrup and Loratadine 24 tablets. NAFDAC said the medicines were classified as substandard or adulterated — a category of quality violations cited by the Pakistani regulator.

Recalled batches

The list includes Nitras tablets containing glyceryl trinitrate, manufactured by M/s Caraway Pharma in Rawat, batch 24L069. They were classified as substandard.

More current news is available on the UA.News Telegram channel Telegram.

Kadin 2 tablets containing tizanidine hydrochloride, manufactured by M/S FYNK Pharma in Lahore, batch 569, were classified as adulterated. The same classification was given to Acefyl syrup containing acefylline piperazine, manufactured by M/s NABIQASIM Industries in Karachi, batch ACH479, and Loratadine 24 tablets containing loratadine, manufactured by M/S Murfy Pharma in Lahore, batch 24.

NAFDAC measures

The agency said it is monitoring the situation to ensure that the recalled medicines do not enter the Nigerian market. Heads of regional offices and state coordinators were instructed to conduct surveillance and remove these medicines if they are found.

According to NAFDAC, using such medicines may lead to reduced treatment effectiveness, unexpected adverse reactions or treatment failure. The regulator urged people not to buy or use the listed medicines and to purchase medicines only from authorized or licensed suppliers.

Read us on Telegram and Sends

Download our app

PAN's pipeline reviewed approximately 2 open sources for this article. No human editor reviewed this article before publication.

Related Reads

Show on timeline →